CTOs on the Move

PellePharm

www.pellepharm.com

 
We Develop first in class therapies for basal cell carcinomas, including those in gorlin syndrome.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.pellepharm.com
  • 275 Middlefield Road Suite 100
    Menlo Park, CA USA 94025
  • Phone: 510.502.6144

Executives

Name Title Contact Details

Funding

PellePharm raised $20M on 08/01/2017
PellePharm raised $70M on 11/20/2018

Similar Companies

Paige.AI

PAIGE is being built by a dedicated team of Machine Learning experts and pathologists from the leading cancer center in the US and experienced business leadership.

64x Bio

64x Bio is transforming the future of cell and gene therapy manufacturing with high throughput discovery and design of enhanced cell lines for next-generation biomanufacturing and therapeutics.

World Wide Webmasters

World Wide Webmasters is a Clearwater, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ibidi

Ibidi is a Verona, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Switch Therapeutics

Switch Therapeutics is an emerging preclinical stage biotechnology company pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science with the goal of treating a range of diseases – affecting the central nervous system and systemic indications – with significant unmet needs. Switch`s novel gene knockdown approach is based on technology developed by renowned researchers in the field of RNA from Caltech, Harvard and City of Hope. Based on the scientific discovery of Switch`s co-founders, the company has developed a novel proprietary platform known as CASi (Conditionally Activated siRNAs) that combines advantageous properties of both single and double-stranded RNAs in a single molecule, allowing for cell selective RNAi activity. To date, Switch has raised $52M in funding through Series A, and the company`s South San Francisco based team has continued to grow as its research has advanced.